Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders
In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis)....
Gespeichert in:
Veröffentlicht in: | Seminars in immunopathology 2004-02, Vol.25 (3-4), p.237-255 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 255 |
---|---|
container_issue | 3-4 |
container_start_page | 237 |
container_title | Seminars in immunopathology |
container_volume | 25 |
creator | Rook, G A W Adams, V Hunt, J Palmer, R Martinelli, R Brunet, L Rosa |
description | In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis). Because the medical world is so compartmentalised it was some time before the connection between these increases was noticed and understood. There is now evidence that the simultaneous increase in these diseases of immunodysregulation is at least partly attributable to malfunction of regulatory T cells (Treg). This paper provides an overview of relevant work in each of these fields of medicine (though with emphasis on the allergic disorders), and concludes that the increasing failure of Treg is a consequence of diminished exposure to certain micro-organisms that are "old friends", because of their continuous presence throughout mammalian evolution. These organisms, which include saprophytic mycobacteria, helminths and lactobacilli, are recognised by the innate immune system as harmless, and as adjuvants for Treg induction. Polymorphisms of components of the innate immune system such as TLR2 and NOD2 appear to define subsets of the population that will develop immunoregulatory disorders when living in the modern environment. A further role of the "old friends" and of the Treg that they induce might be to maintain the levels of regulatory IL-10 secreting macrophages and antigen-presenting cells, which are depleted in asthma and Crohn's disease. These concepts are leading to novel therapies based on harmless organisms or their components. Phase I/II clinical trials have yielded some statistically significant results, and phase II trials are in progress. |
doi_str_mv | 10.1007/s00281-003-0148-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71711358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>694579361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-eda99162a10eb49932bc67f61d29137558100c6d791e971ecde49af7a6df47223</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMo7rr6A7xI8eAtmknSpjnK4heseNFzSJvp2qVt1qQV9t_bZQuCF08Dw_O-zPAQcgnsFhhTd5ExngNlTFAGMqf6iMwhzwTlgrFjMmdCSioFT2fkLMYNY6BUmp6SGaRjPON6TuzrrvSFLXsMtU1s5xLff2JIsPuug-9a7HrbJD6sbVfHNiY2JnXbDp1vvRsa2_sQk8qHaRlwfVjuEldHHxyGeE5OKttEvJjmgnw8Prwvn-nq7elleb-ipeTQU3RWa8i4BYaF1FrwosxUlYHjGsR4dj6-XGZOaUCtAEuHUttK2cxVUnEuFuTm0LsN_mvA2Ju2jiU2je3QD9EoUAAizf8FQWmhQMsRvP4DbvwQuvEJw0FDnop0D8EBKoOPMWBltqFubdgZYGZvyRwsmdGS2VsyesxcTcVD0aL7TUxaxA9YEo6G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219185354</pqid></control><display><type>article</type><title>Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Rook, G A W ; Adams, V ; Hunt, J ; Palmer, R ; Martinelli, R ; Brunet, L Rosa</creator><creatorcontrib>Rook, G A W ; Adams, V ; Hunt, J ; Palmer, R ; Martinelli, R ; Brunet, L Rosa</creatorcontrib><description>In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis). Because the medical world is so compartmentalised it was some time before the connection between these increases was noticed and understood. There is now evidence that the simultaneous increase in these diseases of immunodysregulation is at least partly attributable to malfunction of regulatory T cells (Treg). This paper provides an overview of relevant work in each of these fields of medicine (though with emphasis on the allergic disorders), and concludes that the increasing failure of Treg is a consequence of diminished exposure to certain micro-organisms that are "old friends", because of their continuous presence throughout mammalian evolution. These organisms, which include saprophytic mycobacteria, helminths and lactobacilli, are recognised by the innate immune system as harmless, and as adjuvants for Treg induction. Polymorphisms of components of the innate immune system such as TLR2 and NOD2 appear to define subsets of the population that will develop immunoregulatory disorders when living in the modern environment. A further role of the "old friends" and of the Treg that they induce might be to maintain the levels of regulatory IL-10 secreting macrophages and antigen-presenting cells, which are depleted in asthma and Crohn's disease. These concepts are leading to novel therapies based on harmless organisms or their components. Phase I/II clinical trials have yielded some statistically significant results, and phase II trials are in progress.</description><identifier>ISSN: 0344-4325</identifier><identifier>ISSN: 1863-2297</identifier><identifier>EISSN: 1863-2300</identifier><identifier>DOI: 10.1007/s00281-003-0148-9</identifier><identifier>PMID: 15007629</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Animals ; Ecosystem ; Humans ; Immune System Diseases - drug therapy ; Immune System Diseases - epidemiology ; Immune System Diseases - immunology ; Immune System Diseases - microbiology ; Immunity, Cellular ; Mycobacterium ; Mycobacterium - immunology</subject><ispartof>Seminars in immunopathology, 2004-02, Vol.25 (3-4), p.237-255</ispartof><rights>Copyright Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-eda99162a10eb49932bc67f61d29137558100c6d791e971ecde49af7a6df47223</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15007629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rook, G A W</creatorcontrib><creatorcontrib>Adams, V</creatorcontrib><creatorcontrib>Hunt, J</creatorcontrib><creatorcontrib>Palmer, R</creatorcontrib><creatorcontrib>Martinelli, R</creatorcontrib><creatorcontrib>Brunet, L Rosa</creatorcontrib><title>Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders</title><title>Seminars in immunopathology</title><addtitle>Springer Semin Immunopathol</addtitle><description>In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis). Because the medical world is so compartmentalised it was some time before the connection between these increases was noticed and understood. There is now evidence that the simultaneous increase in these diseases of immunodysregulation is at least partly attributable to malfunction of regulatory T cells (Treg). This paper provides an overview of relevant work in each of these fields of medicine (though with emphasis on the allergic disorders), and concludes that the increasing failure of Treg is a consequence of diminished exposure to certain micro-organisms that are "old friends", because of their continuous presence throughout mammalian evolution. These organisms, which include saprophytic mycobacteria, helminths and lactobacilli, are recognised by the innate immune system as harmless, and as adjuvants for Treg induction. Polymorphisms of components of the innate immune system such as TLR2 and NOD2 appear to define subsets of the population that will develop immunoregulatory disorders when living in the modern environment. A further role of the "old friends" and of the Treg that they induce might be to maintain the levels of regulatory IL-10 secreting macrophages and antigen-presenting cells, which are depleted in asthma and Crohn's disease. These concepts are leading to novel therapies based on harmless organisms or their components. Phase I/II clinical trials have yielded some statistically significant results, and phase II trials are in progress.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Animals</subject><subject>Ecosystem</subject><subject>Humans</subject><subject>Immune System Diseases - drug therapy</subject><subject>Immune System Diseases - epidemiology</subject><subject>Immune System Diseases - immunology</subject><subject>Immune System Diseases - microbiology</subject><subject>Immunity, Cellular</subject><subject>Mycobacterium</subject><subject>Mycobacterium - immunology</subject><issn>0344-4325</issn><issn>1863-2297</issn><issn>1863-2300</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU1LxDAQhoMo7rr6A7xI8eAtmknSpjnK4heseNFzSJvp2qVt1qQV9t_bZQuCF08Dw_O-zPAQcgnsFhhTd5ExngNlTFAGMqf6iMwhzwTlgrFjMmdCSioFT2fkLMYNY6BUmp6SGaRjPON6TuzrrvSFLXsMtU1s5xLff2JIsPuug-9a7HrbJD6sbVfHNiY2JnXbDp1vvRsa2_sQk8qHaRlwfVjuEldHHxyGeE5OKttEvJjmgnw8Prwvn-nq7elleb-ipeTQU3RWa8i4BYaF1FrwosxUlYHjGsR4dj6-XGZOaUCtAEuHUttK2cxVUnEuFuTm0LsN_mvA2Ju2jiU2je3QD9EoUAAizf8FQWmhQMsRvP4DbvwQuvEJw0FDnop0D8EBKoOPMWBltqFubdgZYGZvyRwsmdGS2VsyesxcTcVD0aL7TUxaxA9YEo6G</recordid><startdate>200402</startdate><enddate>200402</enddate><creator>Rook, G A W</creator><creator>Adams, V</creator><creator>Hunt, J</creator><creator>Palmer, R</creator><creator>Martinelli, R</creator><creator>Brunet, L Rosa</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200402</creationdate><title>Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders</title><author>Rook, G A W ; Adams, V ; Hunt, J ; Palmer, R ; Martinelli, R ; Brunet, L Rosa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-eda99162a10eb49932bc67f61d29137558100c6d791e971ecde49af7a6df47223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Animals</topic><topic>Ecosystem</topic><topic>Humans</topic><topic>Immune System Diseases - drug therapy</topic><topic>Immune System Diseases - epidemiology</topic><topic>Immune System Diseases - immunology</topic><topic>Immune System Diseases - microbiology</topic><topic>Immunity, Cellular</topic><topic>Mycobacterium</topic><topic>Mycobacterium - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rook, G A W</creatorcontrib><creatorcontrib>Adams, V</creatorcontrib><creatorcontrib>Hunt, J</creatorcontrib><creatorcontrib>Palmer, R</creatorcontrib><creatorcontrib>Martinelli, R</creatorcontrib><creatorcontrib>Brunet, L Rosa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rook, G A W</au><au>Adams, V</au><au>Hunt, J</au><au>Palmer, R</au><au>Martinelli, R</au><au>Brunet, L Rosa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders</atitle><jtitle>Seminars in immunopathology</jtitle><addtitle>Springer Semin Immunopathol</addtitle><date>2004-02</date><risdate>2004</risdate><volume>25</volume><issue>3-4</issue><spage>237</spage><epage>255</epage><pages>237-255</pages><issn>0344-4325</issn><issn>1863-2297</issn><eissn>1863-2300</eissn><abstract>In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis). Because the medical world is so compartmentalised it was some time before the connection between these increases was noticed and understood. There is now evidence that the simultaneous increase in these diseases of immunodysregulation is at least partly attributable to malfunction of regulatory T cells (Treg). This paper provides an overview of relevant work in each of these fields of medicine (though with emphasis on the allergic disorders), and concludes that the increasing failure of Treg is a consequence of diminished exposure to certain micro-organisms that are "old friends", because of their continuous presence throughout mammalian evolution. These organisms, which include saprophytic mycobacteria, helminths and lactobacilli, are recognised by the innate immune system as harmless, and as adjuvants for Treg induction. Polymorphisms of components of the innate immune system such as TLR2 and NOD2 appear to define subsets of the population that will develop immunoregulatory disorders when living in the modern environment. A further role of the "old friends" and of the Treg that they induce might be to maintain the levels of regulatory IL-10 secreting macrophages and antigen-presenting cells, which are depleted in asthma and Crohn's disease. These concepts are leading to novel therapies based on harmless organisms or their components. Phase I/II clinical trials have yielded some statistically significant results, and phase II trials are in progress.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>15007629</pmid><doi>10.1007/s00281-003-0148-9</doi><tpages>19</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-4325 |
ispartof | Seminars in immunopathology, 2004-02, Vol.25 (3-4), p.237-255 |
issn | 0344-4325 1863-2297 1863-2300 |
language | eng |
recordid | cdi_proquest_miscellaneous_71711358 |
source | MEDLINE; SpringerNature Journals |
subjects | Adjuvants, Immunologic - therapeutic use Animals Ecosystem Humans Immune System Diseases - drug therapy Immune System Diseases - epidemiology Immune System Diseases - immunology Immune System Diseases - microbiology Immunity, Cellular Mycobacterium Mycobacterium - immunology |
title | Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A38%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mycobacteria%20and%20other%20environmental%20organisms%20as%20immunomodulators%20for%20immunoregulatory%20disorders&rft.jtitle=Seminars%20in%20immunopathology&rft.au=Rook,%20G%20A%20W&rft.date=2004-02&rft.volume=25&rft.issue=3-4&rft.spage=237&rft.epage=255&rft.pages=237-255&rft.issn=0344-4325&rft.eissn=1863-2300&rft_id=info:doi/10.1007/s00281-003-0148-9&rft_dat=%3Cproquest_cross%3E694579361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219185354&rft_id=info:pmid/15007629&rfr_iscdi=true |